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Abstract In this study cationic b-cyclodextrin-chitosan-
mediated nanoparticles were used to transfer pmCherry-C1
into glioblastoma cells and their transfection efficiency were
compared to lipofectamine and electroporation. Physico-
chemical characteristics of nanoparticles were evaluated by
photon correlation spectroscopy and scanning electron
microscopy. Electrophoretic nuclease resistance and stabil-
ity assays were used to check the protection of DNA from
nucleases digestion.mCherry reporter constructwas used for
visualization, followed by quantitation of cell survival and
gene expression by fluorescence-activated cell sorting
analysis and fluorescence microscopy. Particle size was
approximately 200 nm and did not change at 4 C even after
12 weeks. Importantly, the positively charged complexes
interacted with DNA could serve as an efficient DNA
delivery systems. Most of the gene was associated with the
nanoparticles and was efficiently protected from DNAse I
digestion. More than 80 % of transfected cells expressed
mCherry efficiently.
Keywords Chitosan  Cyclodextrin  Gene delivery 
Glioblastoma multiforme  Experimental design
Abbreviations
CS Chitosan
STPP Sodium tripolyphosphate
DMEM Dulbecco’s modified eagle’s medium
FBS Fetal bovine serum
PBS Phosphate-buffered saline
DMSO Dimethyl sulphoxide
pDNA Plasmid DNA
CD b-Cyclodextrin
PCS Photon correlation spectroscopy
LDA Laser doppler anemometry
SEM Scanning electron microscopy
mCh pmCherry-C1 plasmid
CCD Central composite design
FACS Florescence-activated cell sorting
Introduction
Gene delivery systems can be divided into viral, non-viral, and
combined hybrid systems [21]. Non-viral gene delivery sys-
tems were introduced as an alternative to viral-based systems;
where the most important advantage of these systems is
improvement in transfection efficiency [1]. Physical methods
such as electroporation, microinjection, gene gun, and
impalefection, and chemical methods like lipoplexes and
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polyplexes are known as non-viral methods [34]. Physical
methods refer to the delivery of the gene via application of
physical forces to increase permeability of the cell membrane.
Chemicalmethodsutilize natural or synthetic carriers to deliver
genes into cells [32]. Electroporation is temporary destabi-
lization of the targeted cell membrane and genes could be able
to penetrate into the cell [21]. Optimum transfection and sub-
sequent cell viability should be estimated by a number of
experimental variables e.g., cell density, reagent and DNA
concentrations, reagent–DNA complexing time, voltage, and
the pulse in electroporation methods [7]. Felgner and Wu
introduced the use of lipoplexes and polyplexes (complexes of
lipid or polymer with DNA) for the efficient delivery of DNA
through plasma membrane in mammalian cells in 1987 [14].
These vectors rely on the self-assembling; at physiological pH
they are cationic [8] and after removal of small counter ions,
they spontaneously form complexes with anionic nucleic acids
[3].Chemical systemsaremore commonand theyare generally
stable enough to protect nucleic acids from degradation [6].
Liposomes as themost important delivery systems have unique
characteristics e.g., capability to incorporate hydrophilic and
hydrophobic drugs and their low toxicity [20, 21], but the rapid
degradation of liposomes is a drawback of these delivery sys-
tems. Poly (L-lysine), polyethyleneimine, amidoamine den-
drimers, poly (L-histidine), polyvinyl pyridine, and cationic
polysaccharides are cationic polymers which are commonly
used in gene delivery [13]. Cationic polysaccharides are natu-
ral, non-toxic, biodegradable, and biocompatible materials [4].
Most of these conjugates form stable complexes with various
plasmids, and are found active in efficient transfecting cells
in vitro and in vivo. High in vitro transfection efficiency was
achievedwithdextran–spermine conjugates usingdifferent cell
lines [23, 27]. Pullulan–spermine conjugates act as very
promising carriers for deliveringDNAtobrain endothelial cells
[31]. Chitosan as a natural linear copolysaccharide b-(1 ? 4)-
2-amine- 2-deoxy-D-glucose (GlcNac) and b-(1 ? 4)-2-ac-
etamino-2-deoxy-D-glucose (GlcN) exhibits several favorable
biological properties and used in the gene delivery effectively
[28]. In the present study the transfection efficiency of CS/CD/
TPP/pmCherry-C1 complex as gene delivery system was
comparedwith electroporation and lipoplexes delivery systems
as commondelivery systems reported so far, and the conditions
for reproducible stable delivery of exogenous genes into U87
cells, as a mammalian cell model of transfection were also
studied.
Materials and Methods
Chemicals
Materials were purchased from Sigma-Aldrich Company
(Sigma-Aldrich Mo, USA) unless stated otherwise.
Chitosan (low molecular weight, viscosity 20–300 cP,
1 wt% in 1 % acetic acid), sodium tripolyphosphate
(STPP), dulbecco’s modified eagle’s medium (DMEM),
fetal bovine serum (FBS), penicillin–streptomycin
(100 lg/ml), phosphate-buffered saline (PBS), dimethyl
sulfoxide (DMSO), G418 disulfate salt solution and
2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disu-
lfophenyl)-2H-tetrazolium (WST-1 reagent) were all pur-
chased from Sigma-Aldrich. b-cyclodextrin (CD) with
molecular weight Mw = 1135 g/mol were obtained from
Merck Company (Darmstadt, Germany). Plasmid DNA
(pDNA) encoding Cherry fluorescent protein (pmCherry-
C1) driven by a CMV promoter was prepared as instructed
by Invitrogen Corporation (Carlsbad, CA, USA). Lipofec-
tamineTM 2000 reagent was purchased from Invitrogen
Corporation (Carlsbad, CA, USA). U87 glioblastoma cells
were obtained from Pasteur institute of Iran.
Preparation of Chitosan Complex
Nanoparticles were obtained by ionotropic gelification [5].
Two aqueous phases of CS and CD solution with the cross-
linker TPP were mixed under magnetic stirring and main-
tained under agitation to allow complete formation of
system. CS acidic solution (1 % glacial acetic acid) was
prepared at a concentration of 2 mg/ml and the volume
employed was fixed at 3 ml. The corresponding volumes of
the CD aqueous solution (6–12 mg/ml) and TPP solution
(1.5 mg/ml) were mixed at a final volume of 1 ml. For
nanoparticles encapsulating a pDNA model, the required
amount of the plasmid was incorporated directly into the
CD/TPP phase. The theoretical loadings were fixed at 5 %
(w/w, based on the weight of all nanoparticle components:
CS, CD, and TPP).
Chitosan Complex Characterization
Particle size and the size distribution of the nanoparticles
were determined by photon correlation spectroscopy
(PCS). Zeta potential values of the nanoparticles were
obtained by laser doppler anemometry (LDA), measuring
the mean electrophoretic mobility. Samples of the
nanoparticle suspensions were diluted at the appropriate
concentration with filtered water for PCS and with 1 mM
KCl for LDA. PCS and LDA analyses were performed with
a Zetasizer 3000 HS (Malvern Instruments, UK). The
surface and cross-sectional morphology of the chitosan
nanoparticles (sonicated) were analyzed using field emis-
sion scanning electron microscopy (FE-SEM, MIRA 3
XM, Tescan USA Inc.) after sputter coating with gold for
5 min. All samples were examined at an acceleration
voltage of 15 kV. The images were analyzed using the
Image J software to assess the diameter of the chitosan
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nanoparticles. Rheological parameters (shear stress, shear
rate, viscosity) of chitosan were measured by viscometric
measurements using Brookfield Engineering labs DV-III
Ultra Rheometer. The viscometer was operated between 2
and 26 rpm and shear stress, shear rate, and viscosity data
were obtained directly from the instrument; the SC4-18
spindle was selected for the measurement. Viscosity-av-
erage molecular weight was calculated by Mark–Houwink
equation (1) [33]:
g½  ¼ KMav ; ð1Þ
where K = 4.74 9 10-5 (dm3/g) and a = 0.72 determined
in 0.2 M acetic acid solution at 25 C.
The association of pDNA to the nanoparticles was
studied by a conventional agarose gel electrophoresis that
ran for 30 min at 100 V (Sub-Cell GT 96/192, Bio-Rad
Laboratories Ltd., England).
Cytotoxicity Studies
Cells were seeded on each well of 96-well culture dish at a
density of 1 9 104 and incubated for 24 h. One hundred
microliter of theCS/CD/TPP andCS/CD/TPP/pmCherry-C1
composites at the various concentrations of 0.01, 0.05, 0.125,
0.625, 1.25, 2.5, and 5 mg/ml was applied to each well,
followed by 24 h incubation. The medium was refreshed
(100 ll) and 10 ll of WST-1 solution was added and the
cells were allowed to incubate for 3 h. The absorbance of
samples was measured by ELISA reader (BioTek Elx 800)
at 450 nm wavelength and the reference of 630 nm. Absor-
bance of non-treated cells (as control) was estimated as
100 % viability and the treated cells were calculated
according to it. Experiments were replicated four times with
at least three wells for each sample. All samples were run in
three replicates and the experiments were repeated twice.
The survival rate (%) was calculated following Eq. (2) [12]:
% Survival rate ¼ OD in treatment groupð
=OD in control groupÞ  100 ð2Þ
The inhibitory concentration required for 50 % cyto-
toxicity (IC50) value was determined using the Prism
dose–response curve (Prism Graphpad, Prism version 6 for
windows, GraphPad Software, Sa Diego, CA, USA), and
by plotting the percentage of inhibition versus the con-
centration. Lactate dehydrogenase (LDH) release of U87
cells after 24 h incubation with nanoparticles was mea-
sured using the supernatant of the cell culture media by
LDH Cytotoxicity Detection Kit (Pars Azmoon, Tehran,
Iran). The absorbance was read at 492 nm using an auto-
matic analyzer RA-1000 (Technicon, Ireland). All samples
were run in three replicates and the experiments were
repeated twice. Triton X (1 %) was used as positive control
(high control) and untreated cells were used as negative
control (low control). The mortality rate (%) was calcu-
lated following Eq. (3):
Motrality rate %ð Þ ¼ A Cð Þ= B Cð Þð Þ  100; ð3Þ
where A = Test sample - Medium; B = High con-
trol - Volume control; C = Low control - Medium
Transfection Studies
Transfection studies were performed with nanoparticles
loaded with 5 % (w/w) pmCherry-C1 and naked
pmCherry-C1 (positive control). The cells were maintained
at 70 % confluence in 12-well tissue culture plates 24 h
before the experiment. To transfect the cells, they were
washed and freshly prepared CS/CD/TPP and CS/CD/TPP/
pmCherry-C1 nanoparticles (0.625 mg/ml) supplemented
by DMSO (0.5, 0.75, 1, and 1.25 %) were added to 400 ll
cell suspension in 12-well microplate. The plates were
shook gently by shaker (160 rpm/10 min) and incubated
for 24 h. After 24 h the complex was removed and 1 ml of
fresh culture medium was added. The medium was chan-
ged every other time if the experiments exceeded 2 days.
At the indicated time point (48, 72 h), cells were investi-
gated under a fluorescence microscope (Olympus TH 1400)
for the number of Cherry-positive cells. To obtain stably
transfect cells, the samples were incubated first in complete
medium for 72 h and then kept in the complete medium
supplemented with 300 lg/ml G418 solution for 21 days.
Electrophoretic Nuclease Resistance and Stability
Assays
To investigate the ability of the copolymer to protect DNA
from enzymatic degradation, 3 ll of naked pmCherry-C1
(control) and CS/CD/TPP/pmCherry-C1 complexes were
combined with 2 U DNase I in 4 ll 50 mM Tris–HCl at pH
7.6, then incubated for 1 h at 37 C and run on an agarose
gel. For stability assays, CS/CD/TPP/pmCherry-C1 com-
plexes (4 mg/ml) in serum-free medium were prepared and
incubated for up to 7 days. The fluorescent intensity of
bands corresponding to DNA and their electrophoretic
mobility was observed and compared with those obtained
with naked and CS/CD/TPP/pmCherry-C1 complexes in
the absence of serum-free medium.
In Vitro Release Studies
To quantify the DNA release from the obtained nano-
structured systems, 4 mg of CS/CD/TPP/pmCherry-C1
nanoparticles were incubated in PBS (pH 7.4) under gentle
magnetic stirring for 72 h. Samples were centrifuged for
10 min at 13,000 rpm, the supernatant was then removed
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and replaced with fresh PBS. At fixed time points 5, 9, 18,
23, 30 days supernatant was collected, analyzed by spec-
trophotometer, and the kinetic of DNA release from CS/
CD/TPP/pmCherry-C1 nanoparticles was determined.
Stable Transfection by Lipoplexes
Cytotoxicity evaluations were done as described above.
The medium was changed to the fresh medium and the
different volume (1, 1.5, 2, 2.5, and 5 ll) of lipofectamine
solution was applied to each well, follow by 24 h incuba-
tion. The absorbance of non-treated cells was estimated as
100 % viability and for the treated cells was calculated
according to it.
As both the total amount of DNA and the DNA–lipo-
fectamine ratios were important factors in the calculation
of transfection efficiency, various DNA–lipofectamine
(lg:ll) ratios using 2, 4, 8, 16, and 20 lg of mCh plasmid
with different volume of lipofectamine (1, 1.5, 2, 2.5) were
examined. Also, the effects of increasing amounts of mCh
plasmid (0.01–0.1 lg) were measured while maintaining a
constant volume of lipofectamine (2.5 ll according to the
cytotoxicity study). One day before transfection,
0.2–2 9 105 viable cells were cultured in 700 ll DMEM
without antibiotics to attain 90–95 % confluency at the
time of transfection. DNA–lipofectamine complexes were
prepared and diluted in serum-free medium supplemented
with DMSO (0.5, 0.75, 1, and 1.25 %), mixed gently and
incubated for 5–20 min at room temperature. Transfection
complex (200 ll/well) was added to each well and mixed
gently by rocking the plate back and forth. The cells were
incubated for 24–48 h at 37 C; 5 % CO2. Medium was
replaced with complete medium the next day. To obtain
stably transfected cells, the samples were incubated first in
complete medium for 72 h and then in complete medium
supplemented with 300 lg/ml G418 for 21 days.
Stable Transfection by Electroporation
Electroporation was performed using the Eppendorf Mul-
tiporator, which provides a constant square pulse wave
and ease of optimization. Initially, the pulse length and
strength was optimized to limit cell death, while being
intense enough to allow the DNA to cross the cell mem-
brane. For electroporation, the cells were counted and re-
suspended in iso-hypo-osmolar buffer. The appropriate
concentration of DNA, rate of voltage, and the length of the
pulse were chosen according to the experimental design
analysis. After pulsed, cells suspension was spread out in
complete medium with 0.5, 0.75, 1, and 1.25 % DMSO and
then allowed to stand for 5 min at room temperature. After
24 h, the cells were washed twice with PBS and re-fed with
complete medium. To obtain stably transfected cells, the
samples were incubated first in complete medium for 72 h
and then in complete medium supplemented with 300 lg/
ml G418 for 21 days.
Experimental Design and Data Analysis
The central composite design (CCD) was used to investi-
gate the significance of the effects of parameters including
DNA concentration (1, 30.5, 60 lg), voltage (400, 800,
1200 V), and pulses of the exponential wave (30, 165,
300 ls) into three levels (low, basal, and high) as coded
values of -1, 0, ?1 and star points of a = ±1 and the
responses of all 11 experiments were recovered (Table 1).
The main and interaction effects were evaluated in this
design. To find the most prominent effects and interactions,
ANOVAwas calculated using STATISTICA 7.0 software. A
p-value less than 0.05 indicates the statistical significance of
an effect at 95 % confidence level.F test was used to estimate
the statistical significance of all terms in the polynomial
equation within 95 % confidence interval. The mathematical
relationship between the three independent variables was
approximated by the second-order polynomial model Eq. (4):
y ¼ b0 þ
X3
i¼1 biXi þ
X3
i¼1
X3
j¼1 bijXiXj þ
X3
i¼1 biix
2
i ;
ð4Þ
where y is the predicted response (removal percentage) and
Xi’s are the independent variables (DNA concentration,
voltage, and pulse) that were known for each experimental
run. b0 is the model constant, bi is the linear coefficient, bii
is the quadratic coefficient, and bij is the cross-product
coefficient.
Cell Culture
The non-transformed U87 cells were maintained in DMEM
supplemented with 10 % FBS and 100 lg/ml penicillin/
Table 1 Data statistics of model variables
Runs Voltage (v) Pulse (ls) DNA (lg) Removal (%)
1 1200 30 60 0.5
2 800 165 30.5 4.8
3 400 300 1 0.3
4 1200 300 60 0.1
5 400 30 1 2.75
6 1200 30 1 2.75
7 800 165 30.5 4.8
8 800 165 30.5 4.8
9 400 30 60 0.1
10 1200 300 1 0.1
11 400 300 60 0.1
Mol Biotechnol
123
streptomycin at 37 C in a humidified atmosphere with
5 % CO2.
Plasmid Preparation
The pmCherry-C1 plasmid (4.722 kb) encoding Cherry
fluorescent protein driven by a CMV promoter was used.
The pmCherry-C1 was propagated in an Escherichia coli
strain Top 10 (ATCC PTA-10989TM) and purified by
phenol–chloroform method according to the protocol. Both
the yield and purity of the pmCherry-C1 plasmid were
evaluated by UV spectroscopy. The absorbance ratio of
260–280 nm wavelengths for pmCherry-C1 plasmid solu-
tion was measured to be between 1.8 and 2.0.
Isolation of mch1 Single Cells Using Florescence-
Activated Cell Sorting (FACS)
mCh? cells were isolated on a cell sorter (BD FACS
Calibur, USA). Data were acquired on an automated cell
analyzer (LSRII; BD Biosciencs) and analyzed with
WinMDI software (Treestar). Cells were harvested from
the plates using trypsin–EDTA treatment, and were sus-
pended in 3 ml PBS in centrifuge tubes, centrifuged at
1200 rpm for 10 min, and the cell pellet was washed twice
in 3 ml PBS to remove background fluorescence from the
media. Cells were suspended in 0.5 ml PBS and transferred
to flow cytometry cuvettes for analysis. mCh was excited at
587 nm, and emission was detected using a 610/20 band-
pass filter.
Statistical Analysis
Statistical differences were examined using one-way
ANOVA, followed by Tukey test for multiple comparisons.
All analyses were run using the IBM SPSS Statistics
Version 21, and differences between the groups were
judged significant at p\ 0.05.
Results and Discussion
The overall goal of this study was to evaluate the potential
of b-cyclodextrin-grafted chitosan conjugated as a vehicle
for the delivery of the genes of interest to the glioblastoma
cells, and comparing its transfection ability with other
transfection methods such as electroporation and lipo-
plexes. In this regards the ability to associate genes to the
proposed nano-carrier, the interaction of the nano-carrier
with the targeted cells, and the capacity of the gene-loaded
nano-carrier to be expressed in the target cells was taken
into consideration [30]. Results showed that CS/CD/TPP/
pmCherry-C1 complexes are an efficient method for
introducing gene into cells of interest comparing to the
other methods [16]. Near 80 % transfection efficiency was
obtained with optimized conditions, was significantly
higher than that of lipofectamineTM 2000, electroporation,
and naked DNA towards U87 cell line. The experiments
show that, not only transferring gene into target cells using
chitosan-based nanoparticles was considerable, but also
measuring the level of gene transfer was much easier in
comparison with lipoplexes and electroporation because of
their low toxicity and high flexibility.
Stable Transfection by Chitosan Complex
Figure 1 reports the SEM micrographs of CS/CD/TPP and
CS/CD/TPP/pmCherry-C1 complexes. The average diam-
eter of CS/CD/TPP nanoparticles was 200 ± 14 nm
(d = 7 %) (Fig. 1a). Macroscopically CS/CD/TPP/
pmCherry-C1 particles appear as a long chain of interact-
ing particles which are composed of small nanoparticles
(Fig. 1b).
CS/CD nanoparticles were prepared by ionic gelation in
the presence of TPP and the ability of chitosan to gel
rapidly upon contact with TPP relied on the formation of
inter- and intramolecular cross-linkages mediated by the
anionic molecules [25]. The mechanism of formation of the
nano-systems combines the electrostatic interaction
between CS and CDs groups of opposite charge, with the
ability of CS to undergo a liquid–gel transition due to its
ionic interaction with TPP [9]. The results of these
preparation and characterizations indicate that nanoparti-
cles with an average size (200 ± 14 nm) were consistent
with previous findings that chitosan with low molecular
weight produced smaller nanoparticles [17].
Hydrodynamic size readings of the synthesized
nanoparticles as determined by DLS are even more sig-
nificant than values obtained by SEM. Results showed that
the particle size of CS/CD/TPP complexes was approxi-
mately 207 ± 39 nm and did not increase after 12-week
storage at 4 C. The average diameters determined by DLS
were larger than the sizes determined from the SEM ima-
ges for the corresponding samples. This was presumably
because DLS gave the mean hydrodynamic diameter of the
nanoparticle core surrounded by the organic and solvation
layers, whereas SEM gave the diameter of nanoparticles
alone in the dry state. The zeta potential of CS/CD/TPP
was approximately -3.40 mV overall. All complexes
retained a particle size near to 200 nm and positive charge
suitable for efficient cellular uptake [29]. The polydisper-
sity index (PDI) was low, indicating that a homogeneous
dispersion was obtained [26]. PDI was 0.2 in correspon-
dence with the chitosan. Regarding the surface charge,
chitosan samples gave positively charged nanoparticles.
When chitosan, cyclodextrin, and TPP were mixed with
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each other, they formed compact complexes with an
overall positive surface charge, as confirmed by measure-
ments of zeta potential values. Size stability as a function
of time has been studied and the samples presented an
increase in size without formation of large aggregates. The
size evolution during storage is depended on many factors
e.g., particle aggregation which provides a more efficient
rearrangement, the interaction of free polymer chains with
the particle network that leads to a reorganization of
intermolecular entanglements, syneresis, and swelling due
to the presence of TPP that generates an inflow of water by
osmosis [26]. Therefore, the size change is usually due to
balance between the above-mentioned forces. The time
span in which the growing stage finished, is depended on
the size of the initial nanoparticle that is in turn depended
on the molecular weight of chitosan [26].
The relation between shear rate and apparent viscosity is
shown in Fig. 2. The results indicate that the solution
exhibited pseudoplastic fluids behavior, since the viscosity
decreased as shear rate increased. It is related to the
breakage of intermolecular interactions by shearing a typ-
ical behavior of pseudoplastic fluids. These results are in
accordance with the findings of [11].
It was found that chitosan has an average molecular
weight of 4.17 9 105 g/mol determined by viscometry
(Fig. 3) which was increased by increasing its intrinsic
viscosity.
The toxicity of various concentrations of nanoparticles
prepared in this study was evaluated after 24 h incubation
of the trypsinized U87 cells with the transfection
Fig. 1 SEM micrographs of CS/CD/TPP nanoparticles (a) and CS/CD/TPP/DNA complexes (b) (scales 500 nm, 2 lm)
Fig. 2 Influence of the shear rate on the rheological curves of
chitosan solution
Fig. 3 Intrinsic viscosity of chitosan in 0.2 M acetic acid solution at
25 C as a function of Mv determined by viscometry
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complexes, using WST-1 and LDH tests to quantify cell
viability and cell mortality, respectively (Fig. 4). The
results showed that as the concentration of chitosan com-
plexes rose from zero to 5 mg/ml on the basis of the initial
concentration, the survival rate of the U87 cells decreased.
Both the primary effect of the nanoparticles or their side
effects could be responsible for the observed cytotoxicity
[22]. A balance between cell membrane integrity and
cytotoxicity of the therapeutic agent is a crucial aspect in
gene delivery. The survival rate with regard to cytotoxicity
was 70 % at 0.625 mg/ml, with an IC50 value of 4.6 mg/
ml. Chitosan complex showed toxic effect more than 40 %
with concentration 5 mg/ml. It confirmed that nanoparti-
cles did not exhibit any sever toxicity at employed con-
centration (0.652 mg/ml) with LDH test and are in
combination with previous studies [24].
The transfection efficiency of the CS/CD/TPP/
pmCherry-C1 complexes were investigated at varying
concentrations of chitosan complex up to 0.625 mg/ml.
Transfection efficiency increased in the presence of DMSO
and the relative transfections were measured by means of
fluorescence which increased approximately at 1 %
DMSO. The viability of transfected cells with CS/CD/TPP/
pmCherry-C1 complexes with and without DMSO was
approximately 90.0 and 80 % of cells were typically
mCh? (Fig. 5). In a separate experiment, the cytotoxicity
of DMSO in non-transfected cells was tested and it was
found that DMSO had no significant effect on viability up
to 1.25 %, which was the maximum concentration tested.
In vitro transfection efficiency of CS/CD nanoparticles
was found to be dependent on the CS/CD:DNA (w/w)
ratio. The average post-treatment cell viability was C90 %
as nanoparticle dose increased to 0.625 mg/ml [9]. From
the results it was demonstrated that CS nanoparticles were
efficiently internalized into U87 cell line and the uptake
efficiency as measured by flow cytometry was about 80 %.
The ability of the copolymer to entrap pmCherry-C1
plasmid was studied using the agarose electrophoresis
technique. From the photograph of the agarose gel,
depicted in Fig. 6b–d, it could be stated that most of the
DNA plasmid was associated with the nanoparticles, since
no migration of free DNA was observed. Nanoparticles
present a strong fluorescence localized in the well, indi-
cating the formation of adducts, and in correspondence to
the free DNA band, suggesting that DNA might be partially
bound also on the surface of the nanoparticle as expected
[19]. The stability of the nanoparticle complex was eval-
uated 7 days later in the serum-free medium (Fig. 6e).
DNA release from the constructed nano-structured sys-
tems was analyzed by spectrophotometer. At fixed time
points of 5, 9, 18, 23, 30 days the supernatant was col-
lected, and the kinetic of DNA release from CS/CD/TPP/
pmCherry-C1 complexes was measured. The release of
DNA from nanoparticles showed an initial release within
the first 5 days and continued during 9 days of incubation.
DNA was then constantly released up to 30 days with more
than 25 lg of the encapsulated DNA released.
Nanoparticle stability and nucleic acid protection are
important parameters for efficient nucleic acid delivery [2].
Results indicate that our CS formulation was able to protect
DNA plasmid at supra-physiological concentration of
nuclease. Nuclease protection is of great importance for
nucleic acid delivery systems through maintenance of
cargo bioavailability and improved pharmacokinetic pro-
file, thereby increasing the therapeutic potential of these
nanoparticles [2]. According to the agarose gel experi-
ments, most of the DNA was associated with the
nanoparticles, since no migration of free DNA was
observed. This fact is in agreement with the previous
results obtained for other CS-based nanometric systems,
and it can be easily explained by the high affinity of CS for
DNA [2]. Indeed, it is known that the strong electrostatic
Fig. 4 U87 cell viability (WST-1) and mortality (LDH) after treatment with the different concentrations of chitosan complexes in the same
conditions. Data represented as mean ± SD
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interaction exists between the phosphate groups of DNA
and the amino groups of chitosan, as well as hydrophobic
and hydrogen bonds. DNA release study suggests that
nanoparticles are able to encapsulate DNA with improved
efficiency. The maximum release of DNA was 86 % of the
initial feeding amount. The first one, occurring within
9 days is likely due to DNA release from the nanoparticle
surface, while, at a later stage DNA was constantly
released from the core of nanoparticles as a consequence of
chitosan hydration and swelling.
Stable Transfection by Lipoplexes
Up to 2.5 ll of lipofectamine could be used without
affecting cell viability or morphology. Maximum effi-
ciency in constant volume of lipofectamine (2.5 ll) was
found to be occurring on 0.1 lg of mCh plasmid per
12-well microplate. The efficiency of transfection
increased with increasing DNA/lipofectamine ratios. At
20 lg DNA concentrations, the proportion of mCh? cell
was slightly reduced at all DNA/lipofectamine ratio test.
Therefore a combination of 2–4 lg DNA and the highest
possible DNA/lipofectamine ratio of 2.5 ll were used in
subsequent experiments. Transfection efficiency was
monitored for mCh plasmid by fluorescent microscopy
(Fig. 7) and FACS. FACS analysis (38 %) of mCh
revealed an excellent correlation with microscopic
examination.
Fig. 5 Fluorescent and light
micrograph images of
transfected U87 cells. Light
microscopy (a), fluorescence
microscopy (b), merge (c), cells
analyzed by flow cytometry
(d) (scale 200 lm)
Fig. 6 Agarose gel electrophoresis of the nanoparticles encapsulating
plasmid DNA. DNase I digested naked pmCherry-C1 (negative
control) (a) DNase I digested freshly prepared CS/CD/TPP/pDNA
(b) DNase I digested CS/CD/TPP/pDNA in PBS was stable at 4 C
for 3 months, (c) DNase I digested CS/CD/TPP (positive control) (d),
CS/CD/TPP/pDNA in the absence of serum (e), DNA marker (f)
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Lipid-based delivery vectors are developed as most
efficient non-viral methods. Most of them are synthetic
such as lipofectamine, Cellfectin II, HiPerFect, and
FuGENE [18]. They represent a promising approach to
practical gene therapy because of their low toxicity,
biodegradability, high cellular uptake, and easy surface
functionalization [10]. As both the total amount of DNA
and the DNA/lipofectamine ratios were important factors
in transfection efficiency, therefore to achieve the accept-
able lipid-based transfection, the total amount of DNA and
the DNA/lipofectamine ratios were optimized [15]. The
capability of lipofectamineTM 2000 for gene delivery into
U87 cells was analyzed and compared with other methods
as well. U87 cells were transfected at a suitable rate
(37.8 %) in comparison with electroporation method.
The experiments were planned in a random manner to
minimize the effect of uncontrolled variables. ANOVA
was calculated and a p-value less than 0.05 indicate the
statistical significance of an effect at 95 % confidence level
(Table 2).
Data analysis gave a semi-empirical expression of
extraction recovery (ER%) with following Eq. (5):
Fig. 7 Fluorescent and light
micrograph images of
transfected cells with
lipofectamine/pmCherry-C1
plasmid complexes and viewed
24 h later. Light microscopy
(a), fluorescence microscopy
(b), merge (c), cells analyzed by
flow cytometry (d) (Scale:
200 lm)
Table 2 Analysis of variance
(ANOVA) for CCD
Source of variance Sum of squares df Mean square F-value p-value
A-voltage 0.005 1 0.005 3.00 0.1817
B-pulse 3.78 1 3.78 2268.75 \0.0001
C-DNA 3.25 1 3.25 1950.75 \0.0001
AB 0.045 1 0.045 27.00 0.0138
AC 0.045 1 0.045 27.00 0.0138
BC 2.76 1 2.76 1656.75 \0.0001
A2 34.26 1 34.26 20,554.57 \0.0001
B2 0.000 0 0.000
C2 0.000 0 0.000
Lack of fit 0.005 1 0.005
Pure error 0.000 2 0.000
Total SS 44.15 10
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Y ¼ 4:8þ 0:025A 0:69B 0:64C  0:075AB
þ 0:075AC þ 0:59BC  3:96A2 ð5Þ
The transfections (%), as predicted by the final quadratic
model along with the corresponding observed values, are
given in Table 3
Therefore the best electroporation conditions for trans-
fection of mCh were 800 V with time constant of 165 ls
and DNA concentration of 30.5 lg (4 9 105 cells/800 ll
for U87 cell line). Transfection efficiency was monitored
for mCh plasmid, by fluorescent microscopy (5 %) and
FACS (Fig. 8). The FACS analysis (8 %) of mCh revealed
a close correlation with microscopic examination. The
expression of mCh was reduced by time. Longer time
points were tested in this experiment, and the fluorescence
of mCh could persist in cells up to 10 day.
High transfection efficiency in U87 cell lines was
achieved by identifying the most favorable electroporation
voltage and pulse duration. The results confirm that our
refined conditions maximized both transfection efficiency
and cell viability [16]. The best electroporation conditions
for U87 cell line was obtained using an open plate-based
system which allows adjustment of parameters including
voltage and pulse duration. The electroporation conditions
Table 3 Experimental design
and results of the 23 full
factorial central composite
design
Run Variables Transfection
Voltage (v) Pulse (ls) DNA concentration (lg) Experimental Predicted
1 1200 30 60 0.5 0.47
2 800 165 30.5 4.8 4.8
3 400 300 1 0.3 0.33
4 1200 300 60 0.1 0.13
5 400 30 1 2.75 2.73
6 1200 30 1 2.75 2.78
7 800 165 30.5 4.8 4.8
8 800 165 30.5 4.8 4.8
9 400 30 60 0.1 0.13
10 1200 300 1 0.1 0.075
11 400 300 60 0.1 0.075
Fig. 8 Fluorescent and light
micrograph images of
transfected U87 cells. Cells
were electroporated with mCh
plasmid DNA. Bright field
image of U87 cells
(a) fluorescence image,
(b) merge, (c) cells analyzed by
flow cytometry, (d) (scale
1.0 mm)
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reported in this study used voltage setting between 400 and
1200 V and 30 and 300 ls with DNA concentration of 1
and 60 lg. Only 10 % of electroporation efficiency was
obtained with optimized conditions for U87 cells which
was different from previous studies on the other cell lines
[16]. Statistical analysis of uptake efficiency intercell
showed meaningful differences when comparing the CS
nanoparticles with lipoplexes and electroporation methods.
Conclusions
Chitosan-based nanoparticles as non-viral gene delivery
systems was examined on the U87 cells, and compared
with lipoplex and electroporation as common transfection
methods. Besides their great DNA association capacity,
these nanoparticles exhibit low toxicity, deliver the asso-
ciated DNA, and cause high levels of protein expression.
Therefore, results suggest that chitosan-based nanoparticles
might be a safe and efficient non-viral vector for gene
delivery to U87 cell line.
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